Novartis Ag

Sandoz Pharmaceuticals Corp.

Werner Müller

Konstanze Hurth

Dominik Feuerbach

Thomas Josef Troxler

Joachim Nozulak

Mathias Frederiksen

Bernard Lucien Roy

Paul L Herrling

The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C-C, substituted or unsubstituted hetero-C-Caryl, a group N(R)(R), or a group N(R)(CHPR); R represent a hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents a substituted or unsubstituted C-Caryl or a substituted or unsubstituted C-Cheteroaryl; in free base or acid addition salt form. 

1-aza-bicyclo[3.3.1]nonanes

The invention discloses certain substituted .alpha.-aminoacids having the formula ##STR1## where m and n are 1 or 2, and R, R.sub.1, R.sub.2, R.sub.3 and Y have various significances, which compounds are useful in treating epilepsy, disorders associated with excess GH or LH secretion, anxiety, schizophrenia, depression, CNS degenerative disorders, cerebral hypoxic conditions and stress-related psychiatric disorders.

Use of certain substituted .alpha.-amino acids in treating

.alpha.-amino-.alpha.(3-alkyl-phenyl)alkyl ethanoic acids wherein the

Growing community of inventors

Gümligen, Switzerland

Werner Müller